1-[(4-Methyl-1-nitroacridin-9-yl)amino]propan-2-yl propanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-[(4-Methyl-1-nitroacridin-9-yl)amino]propan-2-yl propanoate
• 化学式: C20H21N3O4
• 分子量: 367.4
• InChiKey: OCYPFYFWRVVVOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• 9-alkylamino-1-nitroacridine derivatives
  申请人：——

  公开号：US20020099211A1

  公开（公告）日：2002-07-25

  The invention is directed to novel 9-hydroxyalkylamino-, 9-alkoxyalkylamino-1- nitroacridine derivatives. Methods of preparation, pharmaceutical compositions comprising said derivatives and their medical uses are also encompassed by this invention.

  这项发明涉及新颖的9-羟基烷基氨基、9-烷氧基烷基氨基-1-硝基蒽衍生物。该发明还涵盖了制备方法、包含这些衍生物的药物组合物以及它们的医药用途。
• 1-Nitroacridine/tumor inhibitor compositions
  申请人：——

  公开号：US20020037831A1

  公开（公告）日：2002-03-28

  The invention is directed to 1-nitroacridine derivative(s)/tumor inhibitor(s) compositions as well as methods for using said compositions for inhibiting or preventing tumor growth, particularly, prostate cancer cell growth and metastases.

  该发明涉及1-硝基吖啶衍生物/肿瘤抑制剂组合物，以及使用该组合物抑制或预防肿瘤生长的方法，特别是前列腺癌细胞生长和转移。
• 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES
  申请人：NEW YORK MEDICAL COLLEGE

  公开号：EP1257538A2

  公开（公告）日：2002-11-20
• TUMOR INHIBITING COMPOSITIONS COMPRISING NITROACRIDINES
  申请人：NEW YORK MEDICAL COLLEGE

  公开号：EP1261325B1

  公开（公告）日：2010-09-08
• Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
  申请人：Acerta Pharma B.V.

  公开号：US20170224819A1

  公开（公告）日：2017-08-10

  Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.